• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Shire Plc.

DaVita taps Javier Rodriguez as CEO | Personnel Moves – April 29, 2019

April 29, 2019 By Fink Densford

DaVita Healthcare (NYSE:DVA) said today that its board of directors unanimously elected Javier Rodriguez to succeed Kent Thiry as its new CEO, effective June 1. The Denver-based company said that former CEO Thiry will transition to serve as executive chairman of the board, and that the announcement comes as part of a multi-year succession planning process. […]

Filed Under: Business/Financial News, Featured Tagged With: Avanos Medical (formerly Halyard Health), Baxter, biorad, Clinical Innovations, Corium, DaVita Inc., EarlySense, Electromed, Lantheus, meyerburger, micronsolutions, Shire Plc., The Pew Charitable Trusts

Takeda reaches $62B deal to buy Shire

May 8, 2018 By Sarah Faulkner

After a series of offers, Takeda (TYO:4502) said today that it reached an agreement with Shire (NSDQ:SHPG) to acquire the U.S.-based company in a deal valued at $62 billion. The merger was approved by both companies’ boards of directors, according to Takeda, and is slated to close in the first half of 2019. Takeda investors are wary of the enormous […]

Filed Under: Mergers & Acquisitions, Pharmaceutical, Wall Street Beat Tagged With: Shire Plc., Takeda Pharmaceuticals

Shire accepts $64B takeover bid from Takeda

April 25, 2018 By Fink Densford

 Shire (NSDQ:SHPG) said late yesterday it agreed to Takeda Pharmaceutical‘s (TYO:4502) reworked acquisition bid, now worth approximately $64.2 billion (GBP £46 billion). The takeover offer will now go to Shire’s shareholders for approval, having received backing from Dublin, Ireland-based Shire’s board of directors, according to a press release. Read the whole story on our sister site, […]

Filed Under: Blog Tagged With: Shire Plc., Takeda Pharmaceuticals

Report: Takeda raises $60B offer for Shire, nears prelim acquisition agreement

April 24, 2018 By Fink Densford

Takeda Pharmaceutical (TYO:4502) has sweetened its approximately $60 billion bid for Shire (NSDQ:SHPG) and is approaching a preliminary agreement for acquisition, according to a new report from Bloomberg. The deal could come to a head as early as today, according to the report, as both companies have been working on a tentative agreement and price for the […]

Filed Under: Business/Financial News, Mergers & Acquisitions, Pharmaceutical Tagged With: Allergan, Shire Plc., Takeda Pharmaceuticals

Ex-Advanced BioHealing exec draws probation in VA fraud case

February 12, 2018 By Brad Perriello

A former Advanced BioHealing executive who admitted to federal charges that he bribed U.S. Veterans Affairs Dept. doctors to use the company’s DermaGraft biologic wound dressing last week drew probation in the case. Federal had prosecutors accused Todd Clawson, who left the company in 2012, of participating in a scheme to bribe VA physicians to use the DermaGraft diabetic […]

Filed Under: Legal News, Regenerative Medicine, Wound Care Tagged With: Advanced BioHealing Inc., Shire Plc.

Rani Therapeutics nabs $53m for robotic pill injection tech

February 8, 2018 By Sarah Faulkner

Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its robotic pill technology. New investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG) joined existing investors like Alphabet’s GV, Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN). Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Funding Roundup, Pharmaceutical Tagged With: AstraZeneca plc, Novartis, ranitherapeutics, Shire Plc.

How this biotech plans to go up against big pharma with its eye disease products

December 29, 2017 By Sarah Faulkner

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s so much […]

Filed Under: Biotech, Optical/Ophthalmic, Pharmaceutical, Research & Development, Wall Street Beat Tagged With: Allergan, Massachusetts Eye & Ear Infirmary, ocugen, Pfizer, Regeneron, Roche, Shire Plc.

Shire taps Rani Therapeutics’ oral delivery tech for hemophilia therapy

December 14, 2017 By Sarah Faulkner

Shire (NSDQ:SHPG) said this week that it is collaborating with Rani Therapeutics to combine the company’s Rani Pill technology for the delivery of factor VIII therapy in patients with hemophilia A. According to the terms of the deal, Shire has the exclusive option to negotiate a license to develop and commercialize the technology as a delivery mechanism for […]

Filed Under: Biotech, Drug-Device Combinations, Pharmaceutical, Research & Development, Wall Street Beat Tagged With: ranitherapeutics, Shire Plc.

Another extended-release ADHD drug wins FDA nod

June 21, 2017 By Sarah Faulkner

Days after Neos Therapeutics (NSDQ:NEOS) nabbed U.S. regulatory approval for its controlled-release formulation of methylphenidate, Shire (NSDQ:SHPG) said it won a nod from the FDA for its long-acting ADHD drug. The drug, Mydayis, is made up of the same active ingredient in Shire’s ADHD treatment Adderall XR – amphetamine – but it is designed to last up to […]

Filed Under: Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: neostherapeutics, Shire Plc.

Navigating the regulatory and development pathways for drug-device products

May 18, 2017 By Sarah Faulkner

David Lee began his path to CEO of Lumicell in 1999, when his wife was diagnosed with cancer. She passed away in 2003, while Lee was working in the semiconductor industry. He decided it was time for a career change. More than a decade later, Lee holds the corner office at a company that is […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: cocoonbiotech, Ethicon, Lumicell, panthertherapeutics, Shire Plc.

Shire to pay feds $350m to settle DermaGraft kickbacks case

January 12, 2017 By Sarah Faulkner

The U.S. Justice Dept. said yesterday that Shire (NSDQ:SHPG) and its subsidiaries will cough up $350 million to settle allegations that Shire and the company it acquired in 2011, Advanced BioHealing, gave kickbacks to clinics and physicians in exchange for using its bioengineered human skin substitute, Dermagraft. “This settlement represents the largest False Claims Act recovery by the […]

Filed Under: Diabetes, Legal News, Pharmaceutical, Wall Street Beat Tagged With: Advanced BioHealing Inc., Shire Plc., U.S. Justice Dept. (DOJ)

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS